# Step 133 — DE09.003 manual acceptance evidence closure

2026-10-22. **DE09.003: SATISFIED — VERIFIED (qualifications)** for the native provider-entered medicine-name storage and read-only Prescription Details display contract. **PC07.01: PARTIAL.** Inventory before/after: **10 mandatory-gap IDs / three packages**. This is a bounded engineering evidence decision, not external certification acceptance or a deployment-wide assertion.

## Git checkpoint and execution boundary

Read AGENTS.md and the relevant evidence in [Step 130](197-step130-de09-003-prescription-brand-trade-name-evidence-correlation.md), [Step 131](198-step131-de09-003-recorded-medicine-name-display-contract-resolution.md) and [Step 132](199-step132-de09-003-recorded-brand-name-details-display-fix.md). Recorded branch `main`, HEAD `b7fa5d7c12bcecc76a04f44ab40012495238218d`, and working-tree status once:

```text
 M src/MicroEMR.Web/Views/PatientPrescriptions/Detail.cshtml
?? docs/certification/199-step132-de09-003-recorded-brand-name-details-display-fix.md
?? tests/MicroEMR.Api.Tests/PrescriptionDetailDisplayTests.cs
```

Report number 200 was available. Those existing changes are preserved. This step adds only this report. Targeted read-only evidence/source/result inspection and documentation only: no implementation, new tests, test execution, build, SQL connection/write, fixture/clinical action, browser/API action, service restart, staging, commit, branch operation or remote operation.

## Requirement and implementation evidence

Reuse Steps 130–131's authoritative interpretation of CDS-S Data Dictionary 2.1 Final, row 128: DE09.003 Brand Name is mandatory Store/Display support for the Canadian-marketed name from a drug database **or the medicine name typed by the provider**. A compulsory catalogue lookup, exact typography and placement on every output are not established by that row. Generic Name, custom/complex Drug Description and DIN remain separate obligations.

Step 130 established independent ProductName persistence, DTO/repository transport, separate ProductDisplayText and GenericName, and historical native typed-input execution evidence. Step 131 resolved the omitted recorded-name display contract. Step 132 added the explicit line in [Detail.cshtml](../../src/MicroEMR.Web/Views/PatientPrescriptions/Detail.cshtml):

```cshtml
<p><strong>Product/Brand Name:</strong> @rx.ProductName</p>
```

Targeted inspection confirms that binding remains present. It directly displays the already-returned recorded name, with normal Razor encoding and blank empty/null rendering. Product Display retains its independent heading; there is no inferred generic/display fallback. No schema, storage, signing, correction, historical output or authorization change was necessary.

## Reused automated evidence

Step 132's retained `.tmp/step132/step132-focused.trx` counters were read, not rerun: **18 executed, 18 passed, 0 failed, 0 not executed**. These comprise ten `PrescriptionDetailDisplayTests` cases and eight existing `PrescriptionPrivateNoteWebTests` cases. The initial harness routing failure and successful final rerun remain documented in Step 132.

Inspection of the existing rendered-view test confirms coverage for both Draft and Finalized status with distinct ProductName/ProductDisplayText/GenericName, provider-typed text containing markup-sensitive punctuation, blank display with a recorded name, empty recorded name and null recorded name. Assertions verify the explicit recorded value, independent display heading, encoding, status badge and absence of editing controls. These are synthetic DTO rendering tests; they do not establish the provenance of a particular screenshot's name or a live catalogue selection.

For storage/input, reuse Step 130's recorded historical Step 118 PASS evidence for `HttpRoundTripKeepsGenericSeparateAndUnknownHonest`. Targeted test-source inspection confirms explicit independent ProductName and ProductDisplayText create-response assertions. Subsequent GET/list assertions focus on GenericName; they are not recast as finalized brand-specific comparisons. Existing lifecycle tests support artifact retention, not a newly executed end-to-end brand test. Together with the established storage/read mapping, direct render binding and owner UI observations, these provide the necessary chain without another clinical save/sign cycle.

## Owner-confirmed manual acceptance

Source: the owner's Step 133 request reports screenshots reviewed with the owner for two existing fictional development prescriptions. The observations below are accepted as owner-confirmed evidence. Codex did not independently execute browser testing or inspect screenshot files in this step; no screenshot filenames, tenant identifiers, prescription identifiers or capture timestamps were supplied. No such metadata is invented.

| Observation | Draft Details | Finalized Details |
|---|---|---|
| Status | Draft | Finalized |
| Product Display | `TEST ONLY date precision tablet` | `TEST ONLY date precision tablet` |
| Product/Brand Name | `TEST ONLY date precision` | `TEST ONLY date precision` |
| Independent values and visible Product/Brand Name label | Confirmed | Confirmed |
| Readable layout | Confirmed | Confirmed |
| Existing private-note presentation | Section remains visible | Read only displayed; history control remains available |
| Owner acceptance result | **PASS** | **PASS** |

These observations corroborate saved read-only presentation in both states. They do not prove a particular creation path, catalogue provenance, note-edit authorization or all historical lifecycle/security behavior.

## Qualifications and closure reasoning

| Remaining limit | Disposition |
|---|---|
| Provider-typed provenance of the two observed records is not independently established | No screenshot provenance PASS. Typed-input support is supported separately by historical API/storage evidence; Step 132 verifies rendering arbitrary supplied names. The authoritative typed-name alternative is adequately supported in the native path. |
| Manual empty/null presentation not observed | Automated render cases pass for both states. Manual blank/null acceptance remains unverified, without blocking this display correction. Blank handling is defensive behavior, not permission to omit a known recorded name. |
| All catalogue variants/provenance not verified | No catalogue-wide closure. Catalogue lookup is not compulsory for the supported typed-name alternative; DIN capability remains a separate requirement. |
| General deployment applicability not verified | Closure applies to the inspected local implementation/evidence chain. It does not attest deployment of these uncommitted changes elsewhere. |
| Historical source/release and broader evidence qualifications | Retain Steps 115/128–131 qualifications, including accepted-release applicability. No external OntarioMD acceptance or broader PC07.01 closure is claimed. |
| PDF/CPP/print and other surfaces | No new verification or change. The retained interpretation does not invent a field-specific placement obligation on every output or authorize live enrichment of historical signed artifacts. |

**Decision: DE09.003 — SATISFIED — VERIFIED (qualifications).** The previously blocking assertion was display of the independently stored Product/Brand Name when Product Display differs. Independent storage/input evidence, the explicit ProductName binding, focused rendered regression PASS results and owner-confirmed Draft/Finalized unequal-value observations now support that assertion. Remaining limits above are nonblocking for this bounded native typed-name Store/Display obligation. No unsupported scenario is assigned PASS, and no further DE09.003 implementation is proposed.

This decision supersedes only DE09.003's outstanding disposition in Steps 130–132. Historical reports remain unchanged; previously closed DE09.019/.023/.026 requirements are not reopened.

## PC07.01, inventory and traceability

**PC07.01 remains PARTIAL.** Closing this subordinate field does not verify Medication DE09 as a whole or PC07.01's full mandatory scope.

**Before: 10 mandatory-gap IDs / three packages. After: 10 mandatory-gap IDs / three packages.** The established count comprises prescribing PC04.01/.06/.07/.09/.14 (5), CPP PC07.01/.04/.07/.10 (4), and scheduling PC09.03 (1). DE09.003 is not a separate top-level counted ID; PC07.01 remains in the inventory. No count reduction or package closure follows.

Use the chronological evidence chain, not a new master matrix: [Step 115 ledger](150-step115-pc07-01-medication-de09-requirement-resolution.md), [Step 117 remaining gaps](152-step117-pc07-01-medication-de09-remaining-gap-prioritization.md), Steps 130–132 and this closure. A later dedicated documentation consolidation would be useful to index superseding dispositions without rewriting historical ledgers; it is not performed here.

## Next outstanding requirement and proposed Step 134

The next unresolved requirement selected from the retained ledger is **DE09.004 — Drug Description**, mandatory Store/Display support for custom compounds or complex prescriptions unsupported by discrete elements. Its exact outstanding assertion is whether existing independently entered ProductDisplayText has the defined custom/complex description meaning and supports the required entry/storage/retrieval/display contract. The existence of free text alone does not establish that mapping. This is a retained semantics/evidence gap, not a newly discovered defect or a claim that every other DE09 element is closed.

**Proposed Step 134: DE09.004 custom/complex Drug Description contract and evidence assessment.** Reuse the retained definition and inspect only the relevant existing contract/evidence to resolve the meaning of ProductDisplayText independently of ProductName and GenericName. Identify the smallest evidence follow-up or separately authorized correction if needed; do not assume a new field, schema change, fixture, clinical action or catalogue is required. This report does not perform that assessment.

Checks for this documentation step: one Git checkpoint; report-number availability; targeted report/source/test-result correlation; owner-evidence attribution; inventory arithmetic; report links, whitespace and final scope review. Only this report added. Stop after documentation.
